Myeloproliferative Neoplasms

Myelofibrosis: From Diagnosis to Early Intervention

In this Case Study, Ms Lyle discusses diagnosis and early management of myelofibrosis in a 72-year-old male patient.

Myeloablative Conditioning Effective in AML Secondary to MDS/MPN Prior to Allogeneic HCT

In the EBMT ALWP study, researchers sought to determine the efficacy of myeloablative conditioning to reduce the risk for post allogeneic HCT in patients with sAML without significantly increasing non-relapse mortality.

Alternate Dosing of Ruxolitinib May Alleviate Anemia in Myelofibrosis

In a phase 2 study, researchers assessed the efficacy of using a dose-escalation approach to lessen the occurrence and severity of anemia in MF treated with ruxolitinib.

Adhering to Cytoreductive Therapy Use May Improve Outcomes in Polycythemia Vera

In a retrospective analysis, researchers sought to determine the use of cytoreductive therapies in patients with high-risk and low-risk PV.

A Case Study on Polycythemia Vera: Diagnosis Through CBC Management With Ruxolitinib

This case follows a 35-year-old man with polycythemia vera from presentation in the ED through initiating and modifying treatment with phlebotomy and hydroxyurea, and eventually achieving optimal management of symptoms and CBC with ruxolitinib.

Effect of Myeloproliferative Neoplasm Diagnosis on Work, Employment Status

Using a cross-sectional online survey, researchers sought to determine how a MPN diagnosis affects work productivity and employment for patients with polycythemia vera, essential thrombocytopenia, or myelofibrosis.

Metformin Plus Ruxolitinib: A Potential Therapeutic Alternative for Myeloproliferative Neoplasms

Researchers investigated the antileukemic activity of metformin and ruxolitinib alone and in combination in patients with myeloproliferative neoplasms.

Ruxolitinib Beneficial in Hydroxyurea Resistant/Intolerant Polycythemia Vera

Data presented at ASH 2017 confirm that ruxolitinib improves hematocrit control, hematologic remission, and reduction in spleen size in some patients with polycythemia vera who fail hydroxyurea.

Ruxolitinib Not Superior to Second-line Treatments for Essential Thrombocythemia

A phase 2 study compared ruxolitinib with best-available therapy as second-line treatment for patients with high-risk essential thrombocythemia or polycythemia vera who became intolerant of first-line therapy.

Complications and Management of Coagulation Disorders in Leukemia Patients

[Blood and Lymphatic Cancer: Targets and Therapy] Investigators conduct 4 case studies that illustrate a range of coagulation disorders that can develop in patients with leukemia to elucidate the rationale and process of specific treatment options.

A Case of Newly Diagnosed PCV After Relapse TTP Complicated by Undiagnosed RA

This case of a 63-year-old African American male with a complicated history illustrates the need for a comprehensive risk assessment of thrombosis in patients with primary polycythemia vera, especially those with concomitant conditions that predispose to thrombosis.

A Patient's Guide to Managing Symptoms of Polycythemia Vera (Fact Sheet)

This fact sheet reviews common symptoms associated with polycythemia vera (PV) and how a patient may address them, along with an overview of more serious symptoms that require medical attention.

Arthritis Medication Shows Potential in the Treatment of Polycythemia Vera

Methotrexate, a medication used commonly in the treatment of arthritis, shows promise as a treatment for polycythemia vera, a blood cancer classified as a myeloproliferative neoplasm.

Decitabine Improves Overall Survival, Overall Response Rate in Chronic Myelomonocytic Leukemia

Patients with high-risk chronic myelomonocytic leukemia (CMML), a MDS/myeloproliferative neoplasm, may experience prolonged overall survival and increased overall response rate from treatment with decitabine.

First Case of Dermatomyositis Associated with Secondary Myelofibrosis Following Polycythemia Vera

A male patient with a history of polycythemia vera that converted to myelofibrosis becomes a first known case of dermatomyositis associated with secondary myelofibrosis.

Unexplained Leukocytosis, Thrombocytosis in MPN Warrants Evaluation for CML

A chart review reveals 3 cases of CML developing in patients with diagnoses of ET and PV.

Impact of ET Treatments on Secondary Malignancies Not Statistically Significant

Treatments for essential thrombocythemia (ET) comprising hydroxyurea and alkylating agents did not appear to impact development of secondary malignancies in patients with ET.

Lack of Transfusion Services a Barrier to Hospice Care for Patients With Blood Cancers

A lack of needed transfusion services was cited as why many hematologic oncologists are less likely to refer their patients with blood cancers to home hospice care.

JAK2 Mutation, Leukocytosis Are Predictive Factors of Thrombosis in Essential Thrombocythemia

Presence of JAK2 mutation and leukocytosis are strong predictors for thromboembolic events in patients with essential thrombocythemia (ET).

Improving Outcomes with Clinical Practice Guidelines for Myeloproliferative Neoplasms

NCCN released its newest Clinical Practice Guidelines in Oncology. These guidelines will assist with preventive, diagnostic, and treatment decisions for patients with myelofibrosis, as well as the other myeloproliferative neoplasms, essential thrombocythemia and PV.

New Predisposition Genes for Familial Polycythemia Vera Are Identified

Predisposition genes for familial polycythemia vera were identified via exome sequencing in a Finnish family with 4 patients.

JAK1, JAK2 Inhibition Improves Outcomes in Myeloproliferative Neoplasms, But More Is Needed

Myelofibrosis, extensive splenomegaly, and symptomatic burden are significantly improved for patients with MPN by JAK1 and JAK2 inhibition; however, some major needs in this patient group are still largely unmet.

Chronic Myeloproliferative Neoplasms Treatment (Fact Sheet)

This fact sheet examines the various kinds of chronic myeloproliferative neoplasms, and the tests utilized to detect and diagnose them.

Importance of GM-CSF Autoantibodies in Pulmonary Alveolar Proteinosis With MPN

A case of simultaneous PAP and MPN diagnoses demonstrate the importance of evaluating for GM-CSF autoantibodies to distinguish autoimmune and secondary forms of PAP.

Genetic Underpinnings of Splanchnic Vein Thrombosis in Myeloproliferative Neoplasms May Provide New Insights

Risk factors for splanchnic vein thrombosis in patients with myeloproliferative neoplasms are multifactorial, involving both environmental and host genetic factors.

Clinical Benefit of Simtuzumab Inconsistent for Myelofibrosis

Simtuzumab is well-tolerated but has inconsistent clinical benefit for patients with myelofibrosis.

Pacritinib More Effective at Spleen Volume Reduction Than Best Available Therapy in Myelofibrosis

Anxiety, Distress Common Among Patients With BCR-ABL-negative MPNs

In this study, researchers measured the psychological manifestations among patients with BCR-ABL-negative MPNs to determine the effects of anxiety, distress, and depression on symptom burden in this patient population.